



RNS Number : 2901I
Roquefort Therapeutics PLC
01 December 2022

1 December 2022

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Resignation of Auditor

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that Jeffreys Henry LLP have notified the Company of their resignation of auditor of the Company.

Jeffreys Henry LLP has advised the Company that it has decided to withdraw from the Public Interest Entity ("PIE") audit market due to increased regulations for PIE auditors. Roquefort Therapeutics is classified as a PIE due to its Standard Listing on the London Stock Exchange's Main Market.

Jeffreys Henry LLP have confirmed that there are no circumstances connected with their resignation which they consider should be brought to the attention of the Company's members or creditors in accordance with Section 519 of the Companies Act 2006.

The Board has identified a new auditor who, subject to standard due diligence and take on procedures will be appointed. It is expected that this process will be completed shortly, at which time the Company will make a further announcement.

-Ends-

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) / Ajan Reginald
(CEO)

+44 (0)20 3918
8633

Hybridan LLP (Joint Broker)

Claire Louise Noyce

+44 (0)203 764
2341**Optiva Securities Limited (Joint Broker)**

Christian Dennis

+44 (0)20 3411
1881**Buchanan (Public Relations)**

Ben Romney / Jamie Hooper / George Beale

+44 (0)20 7466
5000

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- MK cell therapy with direct and NK-mediated anti-cancer action; and
- siRNA targeting novel STAT-6 target in solid tumours showing significant *in vivo* efficacy.

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPBKDBBBDDFBK
Anonymous (not verified)
Resignation of Auditor
33148791
A
Thu, 12/01/2022 - 14:00
LSE RNS
Executive Changes
ROQ